EXPERIENCE WITH COMBINATION TREATMENT FOR GENITAL HERPES IN WOMEN
- Authors: UDZHUKHU V.Y.1
-
Affiliations:
- Russian National Research Medical University, Federal Agency for Health Care and Social Development
- Issue: No 8 (2011)
- Pages: 95-97
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246658
- ID: 246658
Cite item
Open Access
Access granted
Abstract
Objective. To analyze the clinical efficacy of lavomax in combination therapy for genital herpes (GH) with emphasis on its impact on the body’s nonspecific resistance. Subjects and methods. Forty-nine women with GH were followed up. Its diagnosis was verified by enzyme immunoassay and polymerase chain reaction. Results. Immunological studies revealed impairments in the phagocytic component of immunity. The findings suggest that lavomax used in the combination therapy of GH is pathogenetically grounded and effective. Conclusion. Combination therapy using lavomax has a normalizing impact on the body’s natural resistance and rapidly eliminates the clinical manifestations of herpesvirus infection, and achieves a stable clinical resolution.
Keywords
Full Text
About the authors
V. Yu UDZHUKHU
Russian National Research Medical University, Federal Agency for Health Care and Social Development
Email: ail.: sovet140011@mail.ru
Department of Dermatovenereology, Faculty of Pediatrics
References
- Адаскевич В. П. Инфекции, передаваемые половым путем // Руководство для врачей. Н. Новгород: Медицинская книга, Изд-во Нижегородской государственной медицинской академии, 2004.
- Буданов П.В. Проблемы терапии рецидивирующего генитального герпеса // Вопросы гинекологии, акушерствас и перинатологии. — 2004. — Т. 3, № 4. — С. 94—98.
- Hollier L.M., Straub H. Genital herpes //. Clin Evid (Online). — 2011. — Р. 1603.
- Field H.J., Biswas S. Antiviral drug resistance and helicaseprimase inhibitors of herpes simplex virus // Drug. Resist. Updat. — 2011. — Т. 14. № 1. — Р. 45—51.
- Sauerbrei A., Deinhardt S., Zell R. et all. Testing of herpes simplex virus for resistance to antiviral drugs // Virulence. — 2010. — Т. 1, № 6. — Р. 55—57.
Supplementary files
